NCT04655677View on ClinicalTrials.gov

A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

February 28, 2024

Study Completion Date

June 30, 2024

Conditions
B-cell Non-Hodgkin's Lymphoma
Interventions
BIOLOGICAL

Prizloncabtagene Autoleucel

Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously

Trial Locations (1)

100000

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
collaborator

Shanghai AbelZeta Ltd.

INDUSTRY

lead

Peking Union Medical College Hospital

OTHER

NCT04655677 - A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter